Search Results - "Undevia, Samir D"

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas by MAKI, Robert G, D'ADAMO, David R, TAKIMOTO, Chris H, KRAFT, Andrew S, ELIAS, Anthony D, BROCKSTEIN, Bruce, BLACHERE, Nathalie E, EDGAR, Mark A, SCHWARTZ, Lawrence H, QIN, Li-Xuan, ANTONESCU, Cristina R, SCHWARTZ, Gary K, KEOHAN, Mary L, SAULLE, Michael, SCHUETZE, Scott M, UNDEVIA, Samir D, LIVINGSTON, Michael B, COONEY, Matthew M, HENSLEY, Martee L, MITA, Monica M

“…PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in…”
Get full text

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial by Schwartz, Gary K, Prof, Tap, William D, MD, Qin, Li-Xuan, PhD, Livingston, Michael B, Prof, Undevia, Samir D, MD, Chmielowski, Bartosz, MD, Agulnik, Mark, MD, Schuetze, Scott M, MD, Reed, Damon R, MD, Okuno, Scott H, Prof, Ludwig, Joseph A, MD, Keedy, Vicki, MD, Rietschel, Petra, MD, Kraft, Andrew S, Prof, Adkins, Douglas, Prof, Van Tine, Brian A, MD, Brockstein, Bruce, MD, Yim, Vincent, BA, Bitas, Christiana, BA, Abdullah, Abdul, BA, Antonescu, Cristina R, Prof, Condy, Mercedes, RN, Dickson, Mark A, MD, Vasudeva, Shyamprasad Deraje, MA, Ho, Alan L, MD, Doyle, L Austin, Prof, Chen, Helen X, Prof, Maki, Robert G, Prof

“…Summary Background Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The…”
Get full text

Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment by MAITLAND, Michael L, KASZA, Kristen E, KARRISON, Theodore, MOSHIER, Kristin, SIT, Laura, BLACK, Henry R, UNDEVIA, Samir D, STADLER, Walter M, ELLIOTT, William J, RATAIN, Mark J

“…Purpose: Hypertension is a mechanism-based toxicity of sorafenib and other cancer therapeutics that inhibit the vascular endothelial growth factor (VEGF)…”
Get full text

Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan by INNOCENTI, Federico, UNDEVIA, Samir D, VOKES, Everett E, RATAIN, Mark J, IYER, Lalitha, PEI XIAN CHEN, DAS, Soma, KOCHERGINSKY, Masha, KARRISON, Theodore, JANISCH, Linda, RAMIREZ, Jacqueline, RUDIN, Charles M

“…Severe toxicity is commonly observed in cancer patients receiving irinotecan. UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the glucuronidation of the…”
Get full text

Pharmacokinetic variability of anticancer agents by Ratain, Mark J, Undevia, Samir D, Gomez-Abuin, Gonzalo

“…The translation of advances in cancer biology to drug discovery can be complicated by pharmacokinetic variation between individuals and within individuals, and…”
Get full text

Primary Tumor Necrosis Predicts Distant Control in Locally Advanced Soft-Tissue Sarcomas After Preoperative Concurrent Chemoradiotherapy by MacDermed, Dhara M., M.D, Miller, Luke L., B.S, Peabody, Terrance D., M.D, Simon, Michael A., M.D, Luu, Hue H., M.D, Haydon, Rex C., M.D., Ph.D, Montag, Anthony G., M.D, Undevia, Samir D., M.D, Connell, Philip P., M.D

“…Purpose Various neoadjuvant approaches have been evaluated for the treatment of locally advanced soft-tissue sarcomas. This retrospective study describes a…”
Get full text

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies by RYAN, Christopher W, VOGELZANG, Nicholas J, VOKES, Everett E, KINDLER, Hedy L, UNDEVIA, Samir D, HUMERICKHOUSE, Rod, ANDRE, Amy K, QIANG WANG, CARR, Robert A, RATAIN, Mark J

“…Purpose: Atrasentan is an orally bioavailable selective antagonist of the endothelin receptor ET A . Due to the potential activity of this agent against…”
Get full text

Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor : an unusual manifestation of a rare tumor by BAEK, William S, PYTEL, Peter, UNDEVIA, Samir D, RUBEIZ, Helene

“…Malignant peripheral nerve sheath tumors are rare spindle-cell sarcomas derived from Schwann cells or pluripotent cells of the neural crest. They arise from…”
Get full text

Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients by COHEN, Ezra E. W, KEHUA WU, HOUSE, Larry, RAMIREZ, Jacqueline, UNDEVIA, Samir D, FLEMING, Gini F, GAJEWSKI, Thomas F, RATAIN, Mark J, HARTFORD, Christine, KOCHERGINSKY, Masha, NAPOLI EATON, Kimberly, YUANYUAN ZHA, NALLARI, Anitha, MAITLAND, Michael L, FOX-KAY, Kammi, MOSHIER, Kristin

“…Sirolimus is the eponymous inhibitor of the mTOR; however, only its analogs have been approved as cancer therapies. Nevertheless, sirolimus is readily…”
Get full text

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors by Ratain, Mark J., Geary, David, Undevia, Samir D., Coronado, Cinthya, Alfaro, Vicente, Iglesias, Jorge L., Schilsky, Richard L., Miguel-Lillo, Bernardo

“…This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase II trials (P2D) of elisidepsin…”
Get full text

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies by GANGADHAR, Tara C, COHEN, Ezra E. W, FLEMING, Gini F, RATAIN, Mark J, KEHUA WU, JANISCH, Linda, GEARY, David, KOCHERGINSKY, Masha, HOUSE, Larry K, RAMIREZ, Jackie, UNDEVIA, Samir D, MAITLAND, Michael L

“…Sirolimus is the prototypical mTOR inhibitor. Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including VEGF receptor (VEGFR)…”
Get full text

A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours by Undevia, Samir D, Innocenti, Federico, Ramirez, Jacqueline, House, Larry, Desai, Apurva A, Skoog, Linda A, Singh, Deepti A, Karrison, Theodore, Kindler, Hedy L, Ratain, Mark J

“…Abstract Purpose To investigate the safety and pharmacokinetics of R(+)XK469, a quinoxaline analogue, in patients with advanced refractory solid tumours…”
Get full text

A phase I study of continuous infusion cilengitide in patients with solid tumors by O’Donnell, Peter H., Undevia, Samir D., Stadler, Walter M., Karrison, Theodore M., Nicholas, M. Kelly, Janisch, Linda, Ratain, Mark J.

“…Summary Background : Cilengitide (EMD121974) is a cyclized pentapeptide that is a potent and selective integrin antagonist which has shown activity in…”
Get full text

Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease by O'Donnell, Peter H., Artz, Andrew S., Undevia, Samir D., Pai, Rish K., Del Cerro, Paula, Horowitz, Sarah, Godley, Lucy A., Hart, John, Innocenti, Federico, Larson, Richard A., Odenike, Olatoyosi M., Stock, Wendy, Van Besien, Koen

“…Disease recurrence after allogeneic hematopoietic cell transplant (alloHCT) remains common, making improvements in conditioning regimens desirable. A…”
Get full text

The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth by Kakodkar, Nisha C., Peddinti, Radhika, Kletzel, Morris, Tian, Yufeng, Guerrero, Lisa J., Undevia, Samir D., Geary, David, Chlenski, Alexandre, Yang, Qiwei, Salwen, Helen R., Cohn, Susan L.

“…The quinoxaline anti‐tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14‐year old with relapsed…”
Get full text

R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9 by Yong, Wei Peng, Kim, Tae Won, Undevia, Samir D, Innocenti, Federico, Ratain, Mark J

“…Abstract Introduction XK469 is a novel topoisomerase II inhibitor structurally akin to several propionic acid derivatives, such as ibuprofen and diclofenac,…”
Get full text

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital by Innocenti, Federico, Undevia, Samir D., Ramírez, Jacqueline, Mani, Sridhar, Schilsky, Richard L., Vogelzang, Nicholas J., Prado, Marisol, Ratain, Mark J.

“…The anticancer agent irinotecan has been demonstrated to improve the survival rate in patients with metastatic colorectal cancer. Its usage has been limited by…”
Get full text

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors by Undevia, Samir D, Vogelzang, Nicholas J, Mauer, Ann M, Janisch, Linda, Mani, Sridhar, Ratain, Mark J

“…CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-beta-alanyl ester of CEP-751, a potent inhibitor of the trk family of receptor tyrosine kinases and…”
Get full text

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia by Stock, Wendy, Undevia, Samir D., Bivins, Carol, Ravandi, Farhad, Odenike, Olatoyosi, Faderl, Stefan, Rich, Elizabeth, Borthakur, Gautam, Godley, Lucy, Verstovsek, Srdan, Artz, Andrew, Wierda, William, Larson, Richard A., Zhang, Yanming, Cortes, Jorge, Ratain, Mark J., Giles, Francis J.

“…Summary A phase I study was performed to determine the safety and pharmacokinetics of XK469R in patients with refractory acute leukemia. The study aimed to…”
Get full text

Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS) by Chugh, Rashmi, Griffith, Kent A., Brockstein, Bruce, Undevia, Samir D., Stadler, Walter Michael, Schuetze, Scott

“…Abstract only 10028 Background: IGF1R is overexpressed in many STS, but its exact role in the biology of the disease is unclear. Anti-IGF1R antibody…”
Get full text